Veltuzumab: Updated Phase I/II data

Updated data from 39 evaluable chronic ITP patients with platelet counts below 30,000/µL and who failed >=1 standard therapy in an open-label, U.S. Phase I/II trial showed that veltuzumab led to an overall response rate (ORR) of 67%, including an 18% durable complete response rate (n=7). Median relapse-free survival in the 7 complete responders was 1.2 years, with 3 complete responses continuing for 2.3-3.5 years post-treatment. One patient had a grade 3 infusion reaction after receiving an initial 100 mg dose of IV veltuzumab. Veltuzumab was otherwise well tolerated. Patients received 2 doses of 80, 120 or 200 mg IV veltuzumab or 80, 160 or 320 mg subcutaneous veltuzumab given 2 weeks apart. Data were presented at the American Society of Hematology Meeting in San Diego. ...